Company / Cash & Equivalents
Decoy Therapeutics Inc. Cash & Equivalents History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$12.1M
FY2022
5-year range
$3.7M / $29.2M
FY2018-FY2022
Trend
-58.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $11M to $12M over the past 2 years.
Based on SEC 10-K filings.
$12M in FY2022 with a 3-year CAGR of +47.9%.
Improved from $11M to $12M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +47.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +47.9%, indicating consistent growth.
- In FY2022, cash & equivalents decreased 58.6% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $12.1M | -58.6% |
| FY2021 | $29.2M | +162.8% |
| FY2020 | $11.1M | +197.4% |
| FY2019 | $3.7M | -62.0% |
| FY2018 | $9.8M | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026